FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224984865> ?p ?o ?g. }

• W4224984865 endingPage "740" @default.
• W4224984865 startingPage "732" @default.
• W4224984865 abstract "Background & Aims Liver injury related to immunotherapy is a relatively frequent immune-related adverse event that requires permanent discontinuation of immune checkpoint inhibitors (ICIs) in severe cases. We present the outcome of a cohort of patients who were retreated with immunotherapy after resolution of severe immune-related hepatitis. Methods We performed a prospective, multicenter, noninterventional study that included all consecutive patients with cancer and previous grade 3 or 4 immune-related hepatitis who were retreated with ICIs in 3 academic hospitals. Results Twenty-three patients who developed severe immune-related hepatitis were included: 20 of 23 (87.0%) received a single ICI and 3 of 23 (13.0%) received anti-programmed cell death protein-1 plus an anti-cytotoxic T-lymphocyte-associated antigen. The most frequent cancers were lung cell and urinary tract (7 and 6 cases, respectively). Immunotherapy was discontinued in all cases. Nineteen patients (82.6%) also received corticoids. Patients mainly were retreated with the same ICI (18 of 23; 78.3%) after a median time of 10 weeks (range, 1–54 wk) from the severe immune-related hepatitis. Fifteen patients (65.2%) did not have recurrence of the immune-related hepatitis after retreatment. Among the 8 (34.8%) subjects with recurrence, 5 of 8 were grade 3 and 3 of 8 were grade 4. Six (75%) had either an underlying autoimmune disease or antinuclear antibodies ≥1/80 (75% vs 26.7%; P = .037). None of the patients with previously grade 4 hepatitis had a recurrence, and those patients who had a recurrence tended to present with a better oncological prognosis. Overall, 19 (82.6%) subjects required permanent discontinuation of ICIs, with cancer progression the main reason for discontinuation (9 of 19; 47.8%). Conclusions Retreatment with ICIs is a feasible option after a severe immune-related hepatitis, even with the same ICIs, without recurrence of the liver injury retreatment in up to 65% of patients. Liver injury related to immunotherapy is a relatively frequent immune-related adverse event that requires permanent discontinuation of immune checkpoint inhibitors (ICIs) in severe cases. We present the outcome of a cohort of patients who were retreated with immunotherapy after resolution of severe immune-related hepatitis. We performed a prospective, multicenter, noninterventional study that included all consecutive patients with cancer and previous grade 3 or 4 immune-related hepatitis who were retreated with ICIs in 3 academic hospitals. Twenty-three patients who developed severe immune-related hepatitis were included: 20 of 23 (87.0%) received a single ICI and 3 of 23 (13.0%) received anti-programmed cell death protein-1 plus an anti-cytotoxic T-lymphocyte-associated antigen. The most frequent cancers were lung cell and urinary tract (7 and 6 cases, respectively). Immunotherapy was discontinued in all cases. Nineteen patients (82.6%) also received corticoids. Patients mainly were retreated with the same ICI (18 of 23; 78.3%) after a median time of 10 weeks (range, 1–54 wk) from the severe immune-related hepatitis. Fifteen patients (65.2%) did not have recurrence of the immune-related hepatitis after retreatment. Among the 8 (34.8%) subjects with recurrence, 5 of 8 were grade 3 and 3 of 8 were grade 4. Six (75%) had either an underlying autoimmune disease or antinuclear antibodies ≥1/80 (75% vs 26.7%; P = .037). None of the patients with previously grade 4 hepatitis had a recurrence, and those patients who had a recurrence tended to present with a better oncological prognosis. Overall, 19 (82.6%) subjects required permanent discontinuation of ICIs, with cancer progression the main reason for discontinuation (9 of 19; 47.8%). Retreatment with ICIs is a feasible option after a severe immune-related hepatitis, even with the same ICIs, without recurrence of the liver injury retreatment in up to 65% of patients." @default.
• W4224984865 created "2022-04-28" @default.
• W4224984865 creator A5002007245 @default.
• W4224984865 creator A5012972300 @default.
• W4224984865 creator A5016050250 @default.
• W4224984865 creator A5043324785 @default.
• W4224984865 creator A5051482861 @default.
• W4224984865 creator A5058294413 @default.
• W4224984865 creator A5065166501 @default.
• W4224984865 creator A5067553313 @default.
• W4224984865 creator A5086521936 @default.
• W4224984865 date "2023-03-01" @default.
• W4224984865 modified "2023-10-18" @default.
• W4224984865 title "Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study" @default.
• W4224984865 cites W1966268750 @default.
• W4224984865 cites W1972199218 @default.
• W4224984865 cites W2097995306 @default.
• W4224984865 cites W2117692326 @default.
• W4224984865 cites W2155674048 @default.
• W4224984865 cites W2164918836 @default.
• W4224984865 cites W2166662937 @default.
• W4224984865 cites W2736166064 @default.
• W4224984865 cites W2760893760 @default.
• W4224984865 cites W2783137027 @default.
• W4224984865 cites W2786816161 @default.
• W4224984865 cites W2788726176 @default.
• W4224984865 cites W2799571550 @default.
• W4224984865 cites W2831487285 @default.
• W4224984865 cites W2885317131 @default.
• W4224984865 cites W2902412990 @default.
• W4224984865 cites W2908431216 @default.
• W4224984865 cites W2948397884 @default.
• W4224984865 cites W2957570007 @default.
• W4224984865 cites W2988124258 @default.
• W4224984865 cites W3018237426 @default.
• W4224984865 cites W3035638333 @default.
• W4224984865 cites W3038316659 @default.
• W4224984865 cites W3082328886 @default.
• W4224984865 doi "https://doi.org/10.1016/j.cgh.2022.03.050" @default.
• W4224984865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35487453" @default.
• W4224984865 hasPublicationYear "2023" @default.
• W4224984865 type Work @default.
• W4224984865 citedByCount "8" @default.
• W4224984865 countsByYear W42249848652022 @default.
• W4224984865 countsByYear W42249848652023 @default.
• W4224984865 crossrefType "journal-article" @default.
• W4224984865 hasAuthorship W4224984865A5002007245 @default.
• W4224984865 hasAuthorship W4224984865A5012972300 @default.
• W4224984865 hasAuthorship W4224984865A5016050250 @default.
• W4224984865 hasAuthorship W4224984865A5043324785 @default.
• W4224984865 hasAuthorship W4224984865A5051482861 @default.
• W4224984865 hasAuthorship W4224984865A5058294413 @default.
• W4224984865 hasAuthorship W4224984865A5065166501 @default.
• W4224984865 hasAuthorship W4224984865A5067553313 @default.
• W4224984865 hasAuthorship W4224984865A5086521936 @default.
• W4224984865 hasConcept C121608353 @default.
• W4224984865 hasConcept C126322002 @default.
• W4224984865 hasConcept C203014093 @default.
• W4224984865 hasConcept C2776029263 @default.
• W4224984865 hasConcept C2777203481 @default.
• W4224984865 hasConcept C2777382497 @default.
• W4224984865 hasConcept C2777701055 @default.
• W4224984865 hasConcept C2778715236 @default.
• W4224984865 hasConcept C71924100 @default.
• W4224984865 hasConcept C8891405 @default.
• W4224984865 hasConcept C90924648 @default.
• W4224984865 hasConceptScore W4224984865C121608353 @default.
• W4224984865 hasConceptScore W4224984865C126322002 @default.
• W4224984865 hasConceptScore W4224984865C203014093 @default.
• W4224984865 hasConceptScore W4224984865C2776029263 @default.
• W4224984865 hasConceptScore W4224984865C2777203481 @default.
• W4224984865 hasConceptScore W4224984865C2777382497 @default.
• W4224984865 hasConceptScore W4224984865C2777701055 @default.
• W4224984865 hasConceptScore W4224984865C2778715236 @default.
• W4224984865 hasConceptScore W4224984865C71924100 @default.
• W4224984865 hasConceptScore W4224984865C8891405 @default.
• W4224984865 hasConceptScore W4224984865C90924648 @default.
• W4224984865 hasIssue "3" @default.
• W4224984865 hasLocation W42249848651 @default.
• W4224984865 hasLocation W42249848652 @default.
• W4224984865 hasOpenAccess W4224984865 @default.
• W4224984865 hasPrimaryLocation W42249848651 @default.
• W4224984865 hasRelatedWork W1970978650 @default.
• W4224984865 hasRelatedWork W1976893941 @default.
• W4224984865 hasRelatedWork W1982895219 @default.
• W4224984865 hasRelatedWork W2020144630 @default.
• W4224984865 hasRelatedWork W2147462014 @default.
• W4224984865 hasRelatedWork W2335304219 @default.
• W4224984865 hasRelatedWork W2419547539 @default.
• W4224984865 hasRelatedWork W2547634121 @default.
• W4224984865 hasRelatedWork W2896880363 @default.
• W4224984865 hasRelatedWork W4291234481 @default.
• W4224984865 hasVolume "21" @default.
• W4224984865 isParatext "false" @default.
• W4224984865 isRetracted "false" @default.
• W4224984865 workType "article" @default.